Investigating the effects of neoadjuvant chemoimmunotherapy in lung cancer
A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma
This study is testing how a combination of chemotherapy and immunotherapy affects lung cancer patients to see why some tumors resist treatment and how we can improve future therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | Tang-Du Hospital Academic / other |
| Drugs / interventions | immunotherapy, chemotherapy |
| Locations | 1 site (Xi’an, Shanxi) |
| Trial ID | NCT06436040 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the mechanisms behind immunotherapy resistance in lung squamous cell carcinoma (LUSC) by analyzing pre-treatment and post-treatment tumor samples. The research involves collecting tissues from patients undergoing neoadjuvant immunotherapy, specifically anti-PD-1 therapy combined with chemotherapy. Using advanced techniques like single-nucleus RNA sequencing and spatial transcriptomics, the study will create a detailed cell atlas to understand changes in the tumor microenvironment. The findings will help identify predictive markers of treatment response and improve future therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates are patients aged 40 to 80 with operable locally advanced lung squamous cell carcinoma who have not received prior anti-tumor therapy.
Not a fit: Patients with central nervous system metastases, immunodeficiency diseases, or uncontrolled hypertension may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with lung squamous cell carcinoma by identifying factors that influence therapy resistance.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in understanding tumor microenvironments and treatment responses in various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. aged 40 to 80 years; 2. had histologically confirmed LUSC with operable locally advanced stage 3. no prior anti-tumor therapy; received neoadjuvant immunotherapy consisting of three cycles of anti-PD-1 ICB plus nab-paclitaxel and carboplatin 4. pre-treatment tissues Exclusion Criteria: 1. the presence of central nervous system metastases 2. the presence of immunodeficiency disease; previous therapies with immunosuppressants within 14 days prior to the initiation of study treatment; 3. uncontrolled hypertension 4. history of or having pulmonary fibrosis or interstitial lung disease
Where this trial is running
Xi’an, Shanxi
- Hongtao Duan — Xi’an, Shanxi, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.